Risk factors for the development of thrombotic complication in patients with lupus erythematosus and lupus nephropatic;Factores de riesgo para el desarrollo de complicaciones trombóticas en pacientes con lupus eritematoso sistémico y nefropatía lúpica

Revista de Investigacion Clinica

Volumn 65, Issue 3, 2013, Pages 199-208

  Zaldívar Alcántara, Helena ^a   Herrera Jiménez, Luis Enrique ^a   Dehesa López, Edgar ^a   Correa Rotter, Ricardo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiphospholipid antibody syndrome; Lupus erythematosus; Lupus nephritis; Proteinuria; Thrombosis

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; IMAGE ANALYSIS; INCIDENCE; INFLAMMATION; LABORATORY; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIPHOSPHOLIPID SYNDROME; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FUNCTION TESTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROSITIS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84881345373     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opinion Rheumatol 2001; 13(5): 345-51. (Pubitemid 32929862)
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine Baltimore 2003; 83: 299-308. (Pubitemid 37229465)
3. Gustafsson J, Gunnarsson I, Börjesson O, Petterson S, Möller S, Guo-Zhong F, Elvin K, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009; 11: 186.
4. Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al., for the LUMINA Study Group: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-57. (Pubitemid 39643943)
5. Romero-Díaz J, García-Sosa I, Sánchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009; 36(2): 1-8.
6. Kaiser R, Cleveland AM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis Feb 2009; 68: 238-41.
7. Calvo-Alen J, Toloza SMA, Fernandez M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060-08.
8. Tan EM, Cohen As, Fries JF, et al. The 1982 American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
9. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
10. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52(9): 2774-82. (Pubitemid 41369106)
11. Chang ER, Pineau CA, Bernatsky S, et al. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol 2006; 33: 1780-4. (Pubitemid 44373211)
12. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15. (Pubitemid 27084212)
13. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
14. Choojitarom K, Verasertniyom O, Totemchokchyakarn K, et al. Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 2008; 27(3): 345-51.
15. Mercadal L, du Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17: 1771-8. (Pubitemid 35174288)
16. Pasquali S, Banfi G, Zucchelli A, et al. Lupus membranous nephropathy: longterm outcome. Clin Nephrol 1993; 39: 175-82. (Pubitemid 23112538)
17. Mok CC, Tong KH, To CH, et al., Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis. A comparative study. Medicine 2007; 86(4): 203-09. (Pubitemid 47067478)
18. Sisó A, Ramos-Casald M, Bové A, et al. Previous antimalarian therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008; 17: 281-8.
19. Sun HO, Hu WX, Xie HL, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008; 17: 56-61. (Pubitemid 351487021)
20. Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, Kiss E. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year followup. Clin Rev Allergy Immunol 2007; 32(2): 131-7. (Pubitemid 47571435)
21. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16(1): 39-45. (Pubitemid 46174314)
22. Tektonidou MG, Laskari K, Panagiotakos DB. Risk factors for thrombosis and primary thrombosis prevention in patients with SLE with and without antiphospholipid antibodies. Arthritis Rheum 2009; 61(1): 29-36.
23. Danowski A, Leitao de Azevedo MN, et al., Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus. J Rheumatol June 2009; 36(6): 1195-9.
24. Vayá A, Santaolaria M, Micó L, et al. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects. Clin Hemor Microcirc 2008; 40: 79-97.
25. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32. (Pubitemid 36237580)
26. De Laat HB, Derksen RH, Urbanus RT, et al. Beta2 glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-602. (Pubitemid 39564433)
27. De Laat B, Derksen RH, Urbanus RT, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5. (Pubitemid 40223671)
28. Remková A, Remko M. The role of rennin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res 2009; 27.
29. Remková A, Kratochvíl'ová H, Durina J. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 2008; 22(5): 338-45.
30. Erkan D, Lockshin MD. New treatments for antiphospholipid Syndrome. Rheum Dis Clin North Am 2006; 32: 129-48. (Pubitemid 43290595)
31. Durán-Barragán S, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS; LUMINA (LIX): a multiethnic US cohort. Angiotensin- Converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008; 47(7): 1093-06.